Pepti Review: $99 Semaglutide, and an Open Question

Pepti (hellopepti.com) sells 68 prescription SKUs across injectable, oral, nasal and topical routes, and advertises the lowest headline GLP-1 price of any provider we screened in August 2026: $99 a month for injectable semaglutide, $199 for injectable tirzepatide, flat at every titration dose.¹ It also carries a contradiction in its own production data that we could not resolve, and that contradiction is the most important thing on this page.

The advertised ladder

Pepti's pricing is structured as a flat monthly price per SKU, identical whatever dose you titrate to, with an optional one-time purchase at 1.25 times the subscription price. Injectable semaglutide is $99 a month ($124 one-time); injectable tirzepatide is $199 ($249 one-time). Oral semaglutide is $249 and oral tirzepatide $399. Two explicitly labeled longevity microdose SKUs sit at $149 and $229 — read those next to GLP-1 microdosing before assuming a smaller dose is a smaller risk. Subscriptions are cancel-anytime with no minimum term, and can be paused for up to 90 days.

The open question: a second price ladder that renders nowhere

The server payload for Pepti's semaglutide and tirzepatide pages carries a per-dose price array — semaglutide at $299 for 0.25 mg, $349 for 0.5 mg, $399 for 1.0 mg and $449 for 2.4 mg; tirzepatide at $349, $399, $449 and $549. No component on the site reads that array. Nothing renders it. Every visible surface, including the dedicated cost page, says the opposite: one flat price at every dose.¹

We trusted the rendered $99 and $199 in our tables, because that is what the page shows, what the catalog object carries, and what several cross-sell surfaces repeat. But we want to be exact about what that means. A per-dose ladder averaging roughly three times the headline is sitting in this company's live production data, and we could not get to a checkout to find out which one bills you — the checkout endpoint accepts POST only, so it cannot be read without walking a full medical intake. We are reporting the conflict rather than smoothing it, and we are not picking a side. If you enroll, read the amount on the confirmation screen before you accept it, and read it again when you step up a dose.

Two more places the site disagrees with itself

Where Pepti ships is stated two ways. Four separate surfaces — the shipping page, the state-availability page, the provider page, and the homepage title — say 36 states, and publish the list. The terms of service say 50. The 36-state list is corroborated four ways; the terms line is the outlier, and we treat 36 as the operative figure.

When you are charged is also stated two ways. The how-it-works page says you pay nothing until a physician approves your treatment. The refund policy says payment is collected at checkout, before a licensed provider reviews your intake.² The refund policy is the operative document in a dispute, so assume you are charged first and refunded if you are denied. Pepti does state that a provider denial produces a full refund in five to ten business days.

The catalog is much wider than GLP-1

Pepti runs the deepest peptide and nootropic shelf in this batch: BPC-157, TB-500, KPV, KLOW and GLOW blends, CJC-1295 with ipamorelin, sermorelin, tesamorelin, epithalon, MOTS-c, SS-31, DSIP, NAD+ in three routes, and nasal semax, selank, synapsin and VIP. It also sells retatrutide, melanotan II and IGF-1 LR3.

Those last three are the reason this review carries a carve-out. Retatrutide has no FDA approval in any form or jurisdiction; it is an investigational molecule still in trials. Melanotan II and IGF-1 LR3 are not approvable consumer products. Whatever you make of the GLP-1 pricing, none of those three belongs on a shopping list, and their presence tells you something about where this operator draws its line. If you are a tested athlete, note separately that several items on that shelf are prohibited in competition.

Who prescribes, and who dispenses

Pepti names two prescribers with full bios: Dr. Gene Lee, MD, its medical director, board-certified in family medicine and licensed in 26 named states, and Dr. Laeeq Butt, MD MBA, its chief medical officer, internal medicine, licensed in 15 named states. Neither publishes an NPI, so we could not verify either against the national registry — the check described in how to tell if a GLP-1 provider is legit needs a number, and a bio is not one.

The pharmacy is described as "independent FDA-registered 503A or 503B compounding pharmacies" and is never named. Trellis Vitality and The Edit both name theirs. Pepti's legal address is a well-known registered-agent suite in Newark, Delaware, not an operating site — common, and not damning on its own, but worth knowing.

The regulatory screen

Queried against the FDA's live warning-letter index in August 2026, neither the trading name nor the legal entity returns a match in the company column.³ The neighborhood is instructive, though: a broad search on the word "pepti" returns warning letters for a long list of unrelated research-peptide sellers. Pepti is not among them. As with every provider in this batch, the clean result was validated by a positive control that correctly returned a known 2026 letter for a different company in the same pass.

Where it lands

$99 semaglutide is a genuinely notable number, and if it is the number you are billed then Pepti is the cheapest verified GLP-1 rung in this batch by a wide margin — cheaper than Trellis Vitality at $150, Auren Rx at $199 and The Edit at $209. We are publishing it, and we are publishing the unresolved ladder beside it, because a reader deciding on price deserves both. Check the rest of our evidence library, and if the $99 is what matters to you, compare it against the strictly price-sorted cheapest semaglutide ranking.